Locus‐specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma

Authors

Leslie Calapre, Edith Cowan UniversityFollow
Tindaro Giardina
Cleo Robinson
Anna L. Reid, Edith Cowan UniversityFollow
Zeyad Al-Ogaili
Michelle R. PereiraFollow
Ashleigh C. McEvoy, Edith Cowan UniversityFollow
Lydia Warburton
Nicholas K. Hayward
Muhammad A. Khattak
Tarek M. Meniawy
Michael Millward
Benhur Amanuel, Edith Cowan UniversityFollow
Melanie R. Ziman, Edith Cowan UniversityFollow
Elin S. Gray, Edith Cowan UniversityFollow

Author Identifier

Anna Reid

https://orcid.org/0000-0002-4588-1679

Ashleigh McEvoy

https://orcid.org/0000-0001-5692-1317

Mel Ziman

https://orcid.org/0000-0001-7527-3538

Elin Gray

https://orcid.org/0000-0002-8613-3570

Document Type

Journal Article

Publication Title

Molecular Oncology

ISSN

1878-0261

Volume

13

Issue

2

First Page

171

Last Page

184

PubMed ID

30312528

Publisher

John Wiley and Sons Ltd.

School

School of Medical and Health Sciences

RAS ID

27874

Grant Number

NHMRC Number : 1117911

Grant Link

http://purl.org/au-research/grants/nhmrc/1117911

Comments

Calapre, L., Giardina, T., Robinson, C., Reid, A. L., Al‐Ogaili, Z., Pereira, M. R., ... & Meniawy, T. M. (2019). Locus‐specific concordance of genomic alterations between tissue and plasma circulating tumor DNA (ctDNA) in metastatic melanoma. Molecular oncology, 13(2), 171-184. Available here

Abstract

Circulating tumor DNA (ctDNA) may serve as a surrogate to tissue biopsy for noninvasive identification of mutations across multiple genetic loci and for disease monitoring in melanoma. In this study, we compared the mutation profiles of tumor biopsies and plasma ctDNA from metastatic melanoma patients using custom sequencing panels targeting 30 melanoma-associated genes. Somatic mutations were identified in 20 of 24 melanoma biopsies, and 16 of 20 (70%) matched-patient plasmas had detectable ctDNA. In a subgroup of seven patients for whom matching tumor tissue and plasma were sequenced, 80% of the mutations found in tumor tissue were also detected in ctDNA. However, TERT promoter mutations were only detected by ddPCR, and promoter mutations were consistently found at lower concentrations than other driver mutations in longitudinal samples. In vitro experiments revealed that mutations in promoter regions of TERT and DPH3 are underrepresented in ctDNA. While the results underscore the utility of using ctDNA as an alternative to tissue biopsy for genetic profiling and surveillance of the disease, our study highlights the underrepresentation of promoter mutations in ctDNA and its potential impact on quantitative liquid biopsy applications.

DOI

10.1002/1878-0261.12391

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.